Expect more “Shots on Goal” with bispecifics
I said in my blog yesterday that we should rightly be excited about Pfizer’s bet on bispecifics and a week on from their 2024 Oncology Innovation Day, there was a very timely review on bispecifics in Nature Reviews Drug Discovery. Well, would you believe that whilst I was bathing in that excitement, exactly yesterday the 11th March 2024 the same team of Christian Klein et al published online yet another review on bispecifics! Keep them coming, guys! Just look at the insane maths – at the end of 2020, there were only 3 bispecifics approved. Fast forward just 3 years to March 2024 and we’ve pole vaulted to 13 bispecifics approved, around 180 in preclinical development and 50 in clinical studies. If your appreciation of the analogy “shots on goal” is good, then expect more approvals from this single source alone!
READ THE ARTICLE – https://www.tandfonline.com/doi/full/10.1080/19420862.2024.2321635